{"filing":{"accession_number":"0001178913-26-003442","cik":"0001534248","ticker":"CMMB","company_name":"Chemomab Therapeutics Ltd.","form":"6-K","filing_date":"2026-07-08","report_date":null,"primary_document":"zk2635653.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891326003442/zk2635653.htm"},"events":[{"id":16600,"run_id":14832,"accession_number":"0001178913-26-003442","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"This exhibit announces a definitive merger agreement between Chemomab Therapeutics and Scipher Medicine Corporation, a material acquisition/change of control transaction. The press release discloses entry into the merger agreement, the stock-for-stock transaction structure, ownership percentages (32% Chemomab, 68% Scipher post-closing), a concurrent $30 million private placement, expected closing in Q4 2026, and contingent value rights for Chemomab shareholders. This is a classic material M\u0026A event requiring disclosure under Item 1.01 or 2.01 of an 8-K equivalent.","company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","filing_date":"2026-07-08","form":"6-K","submitted_at":null,"items":[{"id":14752,"accession_number":"0001178913-26-003442","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This exhibit announces a definitive merger agreement between Chemomab Therapeutics and Scipher Medicine Corporation, a material acquisition/change of control transaction. The press release discloses entry into the merger agreement, the stock-for-stock transaction structure, ownership percentages (32% Chemomab, 68% Scipher post-closing), a concurrent $30 million private placement, expected closing in Q4 2026, and contingent value rights for Chemomab shareholders. This is a classic material M\u0026A event requiring disclosure under Item 1.01 or 2.01 of an 8-K equivalent.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:35:37.890457+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14752,"accession_number":"0001178913-26-003442","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This exhibit announces a definitive merger agreement between Chemomab Therapeutics and Scipher Medicine Corporation, a material acquisition/change of control transaction. The press release discloses entry into the merger agreement, the stock-for-stock transaction structure, ownership percentages (32% Chemomab, 68% Scipher post-closing), a concurrent $30 million private placement, expected closing in Q4 2026, and contingent value rights for Chemomab shareholders. This is a classic material M\u0026A event requiring disclosure under Item 1.01 or 2.01 of an 8-K equivalent.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:35:37.890457+00:00","company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","filing_date":"2026-07-08"}]}